Advanced glycation end products (AGEs) have been confirmed to induce bone quality deterioration in diabetes mellitus (DM), and to associate with abnormal expression of miRNAs in DM patients or in vitro. Recently, miRNAs have been recognized to mediate the onset or progression of DM. In the present study, we investigated the regulation on miR-223 level by AGE-BSA treatment in osteoblast-like MC3T3-E1 cells, with real-time quantitative PCR assay. And then we examined the inhibition of insulin-like growth factor 1 receptor (IGF-1R) expression by miR-223, via targeting of the 3 UTR of IGF-1R with real-time quantitative PCR, western blotting and luciferase reporter assay. Then we explored the regulation of miR-223 and IGF-1R levels, via the lentivirus-mediated miR-223 inhibition and IGF-1R overexpression in the AGE-BSA-induced apoptosis in MC3T3-E1 cells. It was demonstrated that AGE-BSA treatment with more than 100 μg/ml significantly up-regulated miR-223 level, whereas down-regulated IGF-1R level in MC3T3-E1 cells. And the up-regulated miR-223 down-regulated IGF-1R expression in both mRNA and protein levels, via targeting the 3 UTR of IGF-1R. Moreover, though the AGE-BSA treatment promoted apoptosis in MC3T3-E1 cells, the IGF-1R overexpression or the miR-223 inhibition significantly attenuated the AGE-BSA-promoted apoptosis in MC3T3-E1 cells. In summary, our study recognized the promotion of miR-223 level by AGE-BSA treatment in osteoblast-like MC3T3-E1 cells. The promoted miR-223 targeted IGF-1R and mediated the AGE-BSA-induced apoptosis in MC3T3-E1 cells. It implies that miR-223 might be an effective therapeutic target to antagonize the AGE-induced damage to osteoblasts in DM.
INTRODUCTION
Diabetes mellitus (DM) is a global metabolic disorder, which is characterized with hyperglycaemia and hyperglycaemiaassociated complications. And various molecules important for the initiation and progression of DM have been recognized. In particular, global proteome profiles of tissue and serum samples from T2DM patients or mouse models have identified lots of proteins, which are associated with the pathogenesis of T2DM [1] [2] [3] [4] . miRNAs are a group of small and non-coding small RNA molecules that bind to the 3 UTRs of target genes and regulate Abbreviations: AGE, advanced glycation end product; DM, diabetes mellitus; H.P .T., hours post-treatment; IGF-1R, insulin-like growth factor 1 receptor; miR-Con, control miRNA; MOI, multiplicity of infection; ROS, reactive oxygen species; RAGE, the receptor for advanced glycation endproducts 1 These two authors contributed equally to this work. 2 To whom correspondence should be addressed (email huiyoshen@163.com).
their expression predominantly at the post-transcriptional level [5, 6] . Recently, miRNAs has been extensively recognized to implicate in the pathogenesis of such diseases as cancers [7] and also DM [7, 8] . miRNAs are abnormally expressed in insulin-targeted organs (liver, muscle and adipose tissues) [9, 10] or circulating blood [8] . And the abnormally-expressed miRNAs mediate or indicate the onset/progression of DM.
Advanced glycation end products (AGEs) develop mainly via the Maillard reaction [11] and are extremely accumulated in DM [12, 13] . And AGEs have been confirmed to contribute to the pathogenesis of multiple diabetic complications such as diabetic retinopathy [14] , diabetic nephropathy [15] and other micro-or marcovascular complications [16, 17] . AGEs are also reported to be associated with the increased risk of bone fracture and delayed fracture healing [18, 19] . In addition, AGEs promote intracellular reactive oxygen species (ROS), the mitogen-activated protein kinase (MAPK) cascade, activate nuclear factor-κB (NF-κB) and AP1 [20] [21] [22] and thus promote the apoptosis [23] [24] [25] in various types of cells [19, 26] . Therefore, the AGEs pose important deregulation on the bone fracture healing in the context of DM.
Far more recently, it has been indicated that AGEs are associated with several miRNAs as miRNA-146a [27] , miRNA-214 [28] and miRNA-223 (miR-223) [29] in DM patients or in vitro. miRNA-214 was recognized to target phosphatase and tensin homologue (PTEN) and mediated the AGE-induced apoptosis in monocytes [28] . And the platelet-secreted miR-223 regulated the endothelial cell apoptosis which was induced by AGEs via targeting the insulin-like growth factor 1 receptor (IGF-1R) [29] . However, it remains to be elucidated whether miRNAs such as miR-223 play a role in the AGE-induced functional changes of osteoblasts.
In the present study, we investigated the miR-223 promotion by AGE-BSA treatment in osteoblast-like MC3T3-E1 cells, and examined the targeting of the 3 UTR of IGF-1R and the inhibition of IGF-1R expression by miR-223. Then we explored the association of miR-223 promotion with the AGE-BSA-induced apoptosis in MC3T3-E1 cells.
EXPERIMENTAL

MC3T3-E1 cell culture and treatment
Mouse osteoblastic MC3T3-E1 cells (A.T.C.C.) were cultured in RPMI 1640 medium (Invitrogen), supplemented with 10 % FBS (Gibco) in a humidified incubator with 5 % CO 2 at 37
• C. Glycoaldehyde-AGE-BSA (AGE-BSA) was purchased from BioVision, with more than 70-folds of glycation than BSA (Sigma-Aldrich), and was dissolved in PBS (pH 7.4) with a concentration of 10 mg/ml before use. For the AGE-BSA treatment of MC3T3-E1 cells, AGE-BSA or BSA was diluted or was dissolved in RPMI 1640 medium with 2 % FBS, with a final concentration of 0, 50, 100, 200 or 400 μg/ml. Then MC3T3-E1 cells which were seeded in a plate with more than 80 % confluence were incubated with the AGE-BSA-or BSA-contained RPMI 1640 medium with 2 % FBS for 0, 6, 12, 24 or 48 h. To promote the miR-223 level in the MC3T3-E1 cells with or without AGE-BSA treatment, miR-223 mimics (mature sequence: 5 -ugucaguuugucaaauacccca-3 , Sigma-Aldrich) or control miRNA (miR-Con; mature sequence: 5 -ugggcguauagacguguuacac-3 , Sigma-Aldrich) were transiently transfected with Lipofectamine RNAiMax (Invitrogen) for 12 or 24 h. To overexpress IGF-1R in MC3T3-E1 cells, the IGF-1R CDS (coding sequence) was cloned into the pcDNA3.1( + ) vector (Invitrogen) with GST as negative control. And the IGF-1R-pcDNA3.1( + ) or control GST-pcDNA3.1( + ) plasmid was transfected into MC3T3-E1 Western blot analysis of IGF-1R 3 x 10 5 MC3T3-E1 cells post-treatment were lysed with the icecold Cell Lysis Buffer (Cell Signaling Technology Inc.); then the cell lysate was centrifuged with 13 600 g at 4
• C for 30 min and was quantified using BCA Protein Assay Reagent Kit (Pierce). Each protein sample was successively subject to the electrophoresis with 10 % SDS/PAGE gradient gel, then transfer to nitrocellulose membrane (Millipore), to the blockage for non-specific binding sites on the membrane with 5 % skimmed milk (4 • C overnight), to the incubation (room temperature for 2 h) with the rabbit polyclonal antibody to IGF-1R (Abcam) or to β-actin (Sigma-Aldrich), and then to the incubation (room temperature for 1 h) with the incubation with horseradish peroxidase-linked secondary antibodies (Pierce). And the specific binding band to IGF-1R or to β-actin was then quantified with ECL detection systems (Thermo Scientific).
Luciferase reporting assay
The 3 UTR of IGF-1R containing the miR-223-targeted sequence (5 -aacugaca-3 ) was amplified from human chromosomal DNA and was cloned into the pGL3-luciferase basic vector (Promega). Each data were averaged for triple independent result, ns: no significance, *P < 0.05, **P < 0.01 or **** P < 0.0001.
MTT assay, apoptosis assay and caspase 3 activity assay control GST-pcDNA3.1( + ) plasmid, with the infection with 2 or 5 MOI of Lenti-miR-223 inhibitor or Lenti-Con virus were collected and were suspended in the 400 μl 1× binding buffer at a concentration of 5×10 5 cells/ml, then 5 μl of Annexin V-FITC and propidium iodide was added in the cell suspension with a incubation at dark for 10 min; and then cells were performed flow cytometry analysis. The apoptotic cells were presented as a percentage to total cells. The caspase 3 activity was performed with the caspase 3 activity assay kit (Roche Diagnostics GmbH) according to the manual. And the activity was expressed as a relative value to control.
Statistical analysis
Statistical analyses were performed using GraphPad Prism 6 (GraphPad Software). The miR-223 level, IGF-1R in mRNA or protein level, the relative luciferase activity, the percentage of apoptotic cells, the caspase 3 activity between two groups were analysed by Student's t test. A P value <0.05 or less was considered significance.
RESULTS
Up-regulation of miR-223 and down-regulation of IGF-1R by AGE-BSA in osteoblast-like MC3T3-E1 cells
To investigate the regulation by AGEs on the miR-223 expression in osteoblasts, we incubated MC3T3-E1 cells with serially-diluted AGE-BSA and examined the miR-223 level with quantitative PCR method. As shown in Figure 1A , the AGE-BSA treatment with more than 100 μg/ml significantly upregulated the miR-223 level in the MC3T3-E1 cells (P < 0.01 or P < 0.0001). And such up-regulation was confirmed in either 6 or 12 h post-treatment (H.P.T.) for 100 μg/ml AGE-BSA (either P < 0.0001, Figure 1B) . It was reported that miR-223 targeted and inhibited IGF-1R in several types of cells [31] [32] [33] ; we then examined the IGF-1R expression in both mRNA and protein levels in the AGE-BSA-treated MC3T3-E1 cells. Figure 1D ). Thus, we found the up-regulation of miR-223 and the down-regulation of IGF-1R in AGE-BSA-treated MC3T3-E1 cells.
miR-223 targets and inhibits IGF-1R in MC3T3-E1 cells
To associate the miR-223 up-regulation with the down-regulated IGF-1R, and to confirm the targeted inhibition of IGF-1R by miR-223 in MC3T3-E1 cells, we then investigated the regulation by miR-223 up-regulation on the IGF-1R expression in MC3T3-E1 cells. It was indicated in Figure 2A that the transfection with 25 or 50 nM miR-223 mimics markedly promoted the miR-223 level at 12 H.P.T. (P < 0.0001 respectively). Moreover, both mRNA (P < 0.01 for 25 or 50 nM, Figure 2B ) and protein (P < 0.01 for 25 or 50 nM, Figures 2C and 2D ) levels of IGF-1R were markedly down-regulated by the transfection with 25 or 50 nM miR-223 mimics. And to reconfirm such targeted down-regulation of IGF-1R by miR-223, we constructed a luciferase reporter with the 3 UTR. Figure 2E demonstrated the high homologous 3 UTR sequence of IGF-1R from Homo sapiens, Mus musculus or Rattus norvegicus; and the sequence of the IGF-1R reporter, with miR-223 target, or the IGF-1R mut reporter, without the miR-223 target was confirmed by sequencing ( Figure 2F ). As shown in Figure 2G , the luciferase assay with IGF-1R reporter demonstrated that the transfection with either 25 or 50 nM miR-223 dramatically down-regulated the luciferase activity than the miRCon (either P < 0.001), whereas there was no such difference between miR-223 and miR-Con, in the context of the luciferase assay with IGF-1R mut reporter. Therefore, we confirmed the targeting inhibition of IGF-1R expression by miR-223 in MC3T3-E1 cells.
AGE-BSA treatment promotes apoptosis in MC3T3-E1 cells
To investigate the influence posed by AGE-BSA treatment on the cell apoptosis, MC3T3-E1 cells were subject to 50, 100, 200 or 400 μg/ml for 48 h, and the cellular viability was examined with Each data were averaged for triple independent result. Statistical significance was considered when P < 0.05 or less, ns: no significance, **P < 0.01, ***P < 0.001 or **** P < 0.0001. MTT assay. Figure 3A indicated that AGE-BSA treatment with more than 100 μg/ml markedly reduced the viability of MC3T3-E1 cells (P < 0.05, P < 0.01 or P < 0.001) dose-dependently (P < 0.05). Compared with the treatment with 200 μg/ml BSA, the 200 μg/ml AGE-BSA reduced the cellular viability at either 24 or 48 H.P.T. (P < 0.05 or P < 0.01, Figure 3B ). Moreover, we examined the apoptosis induction by AGE-BSA treatment with an Annexin V-FITC apoptosis detection kit. As indicated in Figures 3C and 3D, either 100 or 200 μg/ml AGE-BSA treatment for 48 h induced significantly high level of apoptotic cells (P < 0.05 or P < 0.001), also dose-dependently (P < 0.01). And such apoptosis induction was repeatedly found at either 24 or 48 H.P.T. for 200 μg/ml AGE-BSA, rather than 200 μg/ml BSA (P < 0.05 or P < 0.001, Figure 3E ). In summary, AGE-BSA treatment reduces cellular viability and promotes apoptosis in MC3T3-E1 cells.
IGF-1R overexpression inhibits the AGE-BSA-promoted apoptosis in MC3T3-E1 cells
To explore the regulatory role of IGF-1R in the AGE-induced apoptosis of MC3T3-E1 cells, we then overexpressed IGF-1R in MC3T3-E1 cells via gain-of-function strategy. The IGF-1R coding sequence-carried IGF-1R-pcDNA3.1( + ) or the control GSTpcDNA3.1( + ) plasmid was transfected into MC3T3-E1 cells to manipulate the IGF-1R level. It was demonstrated that there was a significant up-regulation of IGF-1R in both mRNA (P < 0.001 for either 6 or 12 H.P.T., Figure 4A ) and protein levels (either 24 or 48 H.P.T., Figure 4B ) post the transfection with IGF-1R-pcDNA3.1( + ) transfection in MC3T3-E1 cells, compared with the GST-pcDNA3.1( + ) transfection. In addition, the apoptotic cells and relative caspase 3 activity were also assayed in MC3T3-E1 cells which were transfected with each type of recombinant plasmid. Figure 4C Figure 5A confirmed the marked reduction of miR-223 by the Lenti-miR-223 inhibitor virus infection with 2 or 5 MOI (P < 0.01 respectively). And the miR-223 inhibition also blocked the IGF-1R reduction in the MC3T3-E1 cells which were treated with 200 μg/ml AGE-BSA in both mRNA (P < 0.05 or P < 0.01, Figure 5B ) and protein (P < 0.05 or P < 0.01, Figures 5C and  5D ) levels. Moreover, as expected, the apoptosis induction was markedly reduced by the miR-223 inhibition with either 2 or 5 MOI Lenti-miR-223 inhibitor virus (P < 0.05 or P < 0.01, Figure 5E ). And the caspase 3 activity promotion by 200 μg/ml AGE-BSA was also attenuated by the Lenti-miR-223 inhibitor virus infection with either 2 or 5 MOI (P < 0.05 or P < 0.01, Figure 5E ). Therefore, we confirmed the mediatory role of miR-223 in the AGE-BSA-induced apoptosis in MC3T3-E1 cells via targeting IGF-1R.
DISCUSSION
AGEs promote apoptosis in various types of cells, such as fibroblasts, renal tubular cells and endothelial cells [34] [35] [36] . And recently, AGEs have been recognized to involve in the bone quality deterioration in DM, via promoting bone loss [37] , bone fragility [38] and impairment to fracture healing [18, 19] . Oxidative stress and the generation of AGEs have emerged as links between inflammation and bone destruction in DM [37] . Accumulated AGEs along with impaired collagen cross-linking and the suppression of bone turnover seem to be significant factors impairing bone strength [38] . In particular, the inflammation aroused by ROS and AGEs increases chondrocyte and osteoblast death and prolongs osteoclast survival, resulting in impaired bone regeneration in DM [19] . AGEs also up-regulated the expression of both the receptor for advanced glycation endproducts (RAGE) and galectin-3 and induced apoptosis in MC3T3-E1 cells [39] . Far more recently, AGEs have been recognized to promote several miRNAs [27] [28] [29] in DM patients or in vitro. In the present study, we firstly confirmed the promotion to miR-223 by AGEs in osteoblast-like MC3T3-E1 cells. And the promoted miR-223 contributed to the AGE-induced apoptosis in MC3T3-E1 cells. miR-223 has been reported to associate with various types of diseases such as cancers [40, 41] , obesity [42] , rheumatoid arthritis (RA) [43] or cardiovascular diseases [44] , via targeting tumour suppressor EPB41L3 [40] , targeting HSP90B1 [41] or targeting cardiac troponin I-interacting kinase [44] . Our study found the high homology of miR-223 with the 3 UTR of IGF-1R with species, such as H. sapiens, M. musculus or R. norvegicus for the first time. And the promoted miR-223 by AGE-BSA treatment in MC3T3-E1 cells down-regulated the IGF-1R in both mRNA and protein levels via targeting the 3 UTR of IGF-1R.
The tumour suppressive role of IGF-1R has been widely recognized in cancer cells [45, 46] , in stem cells [46] . And multiple regulatory roles of IGF-1R have been recognized in osteoblasts, including differentiation [47, 48] and growth [49] . Our further investigation associated the AGE-induced apoptosis in MC3T3-E1 cells with the miR-223 up-regulation and its targeted inhibition to IGF-1R. AGE-BSA treatment significantly reduced the cellular viability and induced apoptosis in MC3T3-E1 cells dosedependently. However, the promoted apoptosis of MC3T3-E1 cells by AGE-BSA was significantly inhibited by the IGF-1R overexpression. The significantly-up-regulated IGF-1R markedly attenuated the induction by AGE-BSA of apoptosis and caspase 3 activity in MC3T3-E1 cells. Moreover, the miR-223 inhibition also ameliorated the AGE-BSA-down-regulated IGF-1R and blocked the AGE-BSA-promoted apoptosis in MC3T3-E1 cells. The infection with lenti-miR-223 inhibitor virus with 2 or 5 MOI blocked the IGF-1R reduction and reduced the AGE-induced apoptosis and the caspase 3 activity in MC3T3-E1 cells.
In summary, our study recognized the promotion of miR-223 by AGE-BSA treatment in osteoblast-like MC3T3-E1 cells. The promoted miR-223 targeted IGF-1R and mediated the AGE-BSAinduced apoptosis in MC3T3-E1 cells. Therefore, we confirmed the mediatory role of miR-223 in the AGE-BSA-induced apoptosis in MC3T3-E1 cells via targeting IGF-1R. It implies that miR-223 might be a effective marker to antagonize the AGEinduced damage to osteoblasts in DM.
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